Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma

Ibrutinib is a Bruton tyrosine kinase inhibitor that is approved by the FDA for the treatment of mantle cell lymphoma and other hematological malignancies. Bruton tyrosine kinases promote platelet aggregation, and, therefore, bleeding is a common side effect of ibrutinib. At least half of patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Locke, Clifford B, Lansigan, Frederick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377008/
https://www.ncbi.nlm.nih.gov/pubmed/32714681
http://dx.doi.org/10.7759/cureus.8743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377008/
https://www.ncbi.nlm.nih.gov/pubmed/32714681
http://dx.doi.org/10.7759/cureus.8743

Ejemplares similares